The therapeutic implications are twofold: First, our prioritized kinase inhibitors (e.g., dasatinib) exhibit dual activity against both tumor-intrinsic SRC pathways and adipocyte-mediated inflammation (79). The gene discussed is SRC; the disease is neoplasm.